Research programme: neurodegenerative disorder therapeutics - Sharp Edge Labs/ Sumitomo Dainippon Pharma
Latest Information Update: 11 Jan 2017
At a glance
- Originator Sharp Edge Labs; Sumitomo Dainippon Pharma
- Class Small molecules
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders